Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Actavis Joins In the Battle for Botox, Valeant Raises Its Bid

Bill Ackman facebook

 

With the hostile takeover saga of Botox-maker Allergan raging on for months, the situation has become even more complicated, with Actavis jumping with a bid for Allergan, as reported by Reuters. It is either Actavis or activist, as in activist investor Bill Ackman, who owns a large stake in Allergan and has been trying to pressure management to succumb to an offer from Valeant, which CEO David Pyott says grossly undervalues his company. As if Pyott is implying there is a price that would be right, the Wall Street Journal reports that Valeant has raised its bid by $15 a share  around $191 per share.

With so many suitors, it is no wonder Allergan’s share price shot up nearly 4%. The irony of this situation is that Allergan was not a struggling company when Ackman and Valeant set their sights on it months ago; usually activists get involved in companies that were struggling, and Allergan’s fundamentals were sound. Perhaps this is a bit of Wall Street theater to boost Ackman’s stake, since psychology often moves stocks more than numbers.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement